Connection

RADEK SKODA to Thrombopoietin

This is a "connection" page, showing publications RADEK SKODA has written about Thrombopoietin.
Connection Strength

2.239
  1. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009 Oct; 94(10):1368-74.
    View in: PubMed
    Score: 0.319
  2. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
    View in: PubMed
    Score: 0.307
  3. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica. 2008 May; 93(5):706-14.
    View in: PubMed
    Score: 0.291
  4. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol. 2000 Jul; 110(1):104-9.
    View in: PubMed
    Score: 0.170
  5. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol. 1999 Nov; 107(2):310-6.
    View in: PubMed
    Score: 0.163
  6. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood. 1999 Aug 15; 94(4):1480-2.
    View in: PubMed
    Score: 0.160
  7. Thrombopoietin production is inhibited by a translational mechanism. Blood. 1998 Dec 01; 92(11):4023-30.
    View in: PubMed
    Score: 0.153
  8. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998 Jan; 18(1):49-52.
    View in: PubMed
    Score: 0.143
  9. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996 Jan 15; 87(2):567-73.
    View in: PubMed
    Score: 0.125
  10. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 2009 Feb 19; 113(8):1768-77.
    View in: PubMed
    Score: 0.076
  11. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005 Jan; 19(1):1-13.
    View in: PubMed
    Score: 0.058
  12. A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem. 2004 Aug 27; 279(35):36397-404.
    View in: PubMed
    Score: 0.056
  13. Chronic myeloproliferative disorders: molecular markers and pathogenesis. Hematol J. 2004; 5 Suppl 3:S122-5.
    View in: PubMed
    Score: 0.054
  14. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci U S A. 1999 Jan 19; 96(2):698-702.
    View in: PubMed
    Score: 0.039
  15. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol. 1998 Sep; 102(5):1341-3.
    View in: PubMed
    Score: 0.038
  16. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
    View in: PubMed
    Score: 0.037
  17. Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost. 2015 Feb; 113(2):414-25.
    View in: PubMed
    Score: 0.029
  18. Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood. 2010 Oct 28; 116(17):3375-6.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.